Bionoia Where life meets thought ⌕
Back to Journal
Journal › Mucosa
Discovery

AKK Study in Improving Obesity and Metabolic Status in Children and Adolescents

Read original paper
Editor's note
Childhood obesity now tracks into adulthood as metabolic disease, yet safe microbiome interventions remain scarce—this trial tests whether restoring *Akkermansia muciniphila*, a mucosa-resident bacterium lost in obesity, can reverse metabolic dysfunction in children. The evidence base exists in adults but remains largely absent in pediatrics, making this a necessary gap-filler rather than breakthrough science. Pediatric gastroenterologists, metabolic specialists, and childhood obesity researchers should watch for safety and durability data when recruitment opens.

Source: ctgov · Central South University · NOT_YET_RECRUITING · 2026-05-18

URL: https://clinicaltrials.gov/study/NCT07593170

AI rationale (4/5, tier: unclassified): Akkermansia muciniphila directly relevant to mucosa barrier biology; study examines microbiome-host signaling in gut.

The problem of obesity among children and adolescents is becoming increasingly serious and may affect their health in adulthood. Researches have found that a type of probiotic in the intestinal tract - "Akkermansia muciniphila" (referred to as AKK), may help regulate metabolism and weight. Although it has shown effects in adults, its safety and efficacy in children and adolescents still need further verification.

This study aims to evaluate the effects of supplementing AKK bacteria on weight, metabolic health and intestinal flora of obese children and adolescents aged 7 to 18.

Related articles in this corpus

Extends
Gut Microbiome in AP Naive
Article B investigates a potential microbiome-based intervention (AKK supplementation) to address the metabolic adverse effects (weight gain, metabolic dysfunction) in youth that Article A identifies as a major concern with antipsychotic medications.
Parallel
Gut microbiota-modulating interventions in paediatric type 1 diabetes: a systematic review and meta-analysis
Both studies investigate probiotic/microbiota-modulating interventions in pediatric populations, but Article A focuses on type 1 diabetes glycemic control while Article B examines Akkermansia muciniphila's effects on obesity and metabolism—distinct disease outcomes sharing a common mechanistic approach.
Parallel
Molecular Pathways and Clinical Applications of Probiotics as Effective Supporters of Intestinal, Neurologic, and Cardiovascular Health: a Narrative Review
Both articles examine probiotics' health benefits through different scopes—Article A focuses on AKK's metabolic effects in children while Article B provides a broader mechanistic review of multiple probiotics across multiple health domains including intestinal and metabolic pathways.
Parallel
Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIV
Both studies investigate weight loss and metabolic improvements in different populations (HIV+ adults vs. children/adolescents) using different interventions (tirzepatide vs. probiotics), with overlapping outcomes but no direct relationship.
Parallel
The Effect of OptiFibre Dietary Fiber on Carbohydrate Metabolism and Intestinal Microbiota Metabolism in Patients With Type 2 Diabetes Mellitus
Both studies investigate gut microbiota-based interventions (fiber and probiotics) to improve metabolic health in different populations, but address distinct mechanisms and patient groups with no direct overlap or dependency.
Published 2026-05-28 · Last kit-update 2026-05-28